Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion)

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2461-2464

  Goto, Shigenori ^a   Shirotani, Noriko ^a   Hatakeyama, Masahiko ^a   Tagami, Chieko ^a   Arakawa, Hiroko ^a   Kuwata, Eri ^a   Noguchi, Katsuo ^a   Egawa, Kohji ^a  

^a Seta Clinic   (Japan)

Author keywords

Activated lymphocyte; Adoptive immunotherapy; Interleukin 2; Non toxic therapy; Stable disease

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL TRANSPLANTATION; CONFERENCE PAPER; FOLLOW UP; HUMAN; HUMAN CELL; INFUSION; JAPAN; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; NEOPLASM STAGING; NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036339442     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Clinical strategies for cancer treatment: The role of drugs
2. FAMTX versus Etoposide, doxorubicin and cisplatin: A random assignment trial in gastric cancer
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. Phase III study of UFT+MMC versus 5FU+CDDP versus 5FU alone in patients with advanced gastric cancer: JCOG study 9205
5. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC Phase III trial
6. Prospects with docetaxel in the treatment of patients with breast cancer
7. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
8. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
9. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
10. Use of adoptive transfer of tumor infiltrating lymphocytes alone or in combination with Cisplatin-containing chemotherapy in patients with epithelial ovarian cancer
11. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma
12. The rationale and practice of CTL therapy against cancer in the mouse and human
13. Longterm growth of lymphokine-activated killer (LAK) cells: Role of anti-CD3, beta-IL-1, interferon-gamma and -beta
14. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2
15. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma
16. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial
17. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes
18. Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer
19. Locoregional cellular immunotherapy for patients with advanced esophageal cancer
20. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterization and clinical utilization
21. Non-surgical therapy for patients with advanced non-small cell lung cancer
22. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
23. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes
24. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
25. Gemcitabine and Vinorelbine in the second-line treatment of non-small cell lung carcinoma patients